Group 2391.png
Frame 427318866.png

ARR, absolute risk reduction; CI, confidence interval; eBC, early breast cancer; ET, endocrine therapy; HER2-, human epidermal growth factor receptor 2 negative; HR, hazard ratio; HR+, hormone receptor positive; iDFS, invasive disease-free survival; LHRH, luteinising hormone-releasing hormone; NSAI, non-steroidal aromatase inhibitor.

Frame 427318444.png

Risk of Recurrence

Risk of Recurrence
See more details
Hide details
Frame 427318444-1.png

Efficacy

Efficacy
See more details
Hide details
Frame 427318444-2.png

Patient Profiles

Patient Profiles
See more details
Hide details
Frame 427318444-3.png

Safety Profile

Safety Profile
See more details
Hide details
Frame 427318444-4.png

Dosing

Dosing
See more details
Hide details
Frame 427318871.png

HR-QoL

HR-QoL
See more details
Hide details
Frame 427318444-5.png

Guidelines

Guidelines
See more details
Hide details

KISQALI® NSS - UAE

PDF
View

References

  1. KISQALI (ribociclib), Prescribing Information.

  2. Fasching PA, et al. Oral LBA13. Presented at the European Society for Medical Oncology Congress 2024, 13–17 September, Barcelona, Spain.